“Obesity will act a major role in colorectal cancer market”
Global colorectal cancer diagnosis and therapeutics market is expected to grow at a CAGR of 4.7% during the forecast period 2018-2023. Market is expected to be $13.8 billion in 2023 and growing due to rising prevalence of colorectal cancer, change in the lifestyle of people such as lack of physical activity, consumption of alcohol, smoking, and consumption of tobacco, inadequate diet, and rising geriatric population. The global colorectal cancer diagnosis and therapeutics market have been segmented by type of cancer, treatment, diagnosis and end users. The report provides detailed and insightful chapters which include market overview, key findings, strategic recommendations, market estimations, market determinants, key company analysis, market insights, company profiling, market segmentation, geographical analysis, and analyst insights of the market.
Full report of global colorectal cancer diagnostics and therapeutics market is available at Global colorectal cancer diagnostics and therapeutics market
Colorectal cancer is the third most common type of cancer globally. As per the American Medical Association, more than 1.6 million cases of colon and rectum cancer has been reported globally. Reported mortality due to colon and rectum cancer is 830,000 in 2015. The North American market is the leading region in terms of revenue. The market value of North America is expected to be $5.3 billion in 2023. The average number of new cases of colorectal cancer is 40.1 per 100,000 men and women per year. Around 4.3% of men and women will be diagnosed with colorectal cancer at some point during their lifetime. In 2017, it is estimated there were 140,000 new cases of colorectal cancer in the US alone.
Obesity is one of the prevailing reasons leading to colorectal cancer. Lack of physical activity along with inappropriate diet lead to obesity. According to cancer organization, people who are obese are slightly (about 30%) more likely to develop colorectal cancer than normal-weight people. Obesity contributes to the increased release of estrogens and a reduction in sensitivity to insulin. The hormones, insulin (IGF-1), and leptin are all elevated in people who are obese and promote the growth of cancer cells. Elevated insulin levels in the body can signal tumor cells to grow and increase the risk of cancer in the bowel. Hence, rising cases of obesity may expand the colorectal cancer cases. According to WHO, in 2016, more than 1.9 billion people of age 18 years and older, were overweight. Out of this, more than 650 million (13%) were obese, and around 39% of adults aged 18 years and over were overweight in 2016. Similarly, about 340 million children in the age range of 5-19 years are obese in 2016. Almost 40% of adults aged 40 to 60 years and above suffer from obesity globally. Colorectal cancer has the highest prevalence rate in this age group, especially 60 years and above.
The report covers
Comprehensive research methodology of Global Colorectal cancer diagnostics and therapeutics market
This report also includes detailed and extensive market overview with key analyst insights.
Exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
Analysis of regional regulations and other government policies impacting the Global Colorectal cancer diagnostics and therapeutics market
Insights about market determinants which are stimulating the Global Colorectal cancer diagnostics and therapeutics
Detailed and extensive market segments with regional distribution of forecasted revenues.
Extensive profiles and recent developments of market players.
For related reports please visit Pharmaceutical Industry